UGC Centre of Advanced Studies, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab 160062, India.
Int J Pharm. 2017 Feb 25;518(1-2):289-306. doi: 10.1016/j.ijpharm.2016.12.044. Epub 2016 Dec 23.
Mangiferin (Mgf), largely expressed out from the leaves and stem bark of Mango, is a potent antioxidant. However, its in vivo activity gets tremendously reduced owing to poor aqueous solubility and inconsistent gastrointestinal absorption, high hepatic first-pass metabolism and high P-gp efflux. The current research work, therefore, was undertaken to overcome the biopharmaceutical hiccups by developing the Mgf-phospholipid complex (PLCs) loaded in nanostructured lipidic carriers (NLCs). The PLCs and NLCs were prepared using refluxing, solvent evaporation and hot emulsification technique, respectively with three molar ratios of Mgf and Phospholipon 90G, i.e., 1:1; 1:2; and 1:3. The complex was evaluated for various physicochemical parameters like drug content (96.57%), aqueous solubility (25-fold improved) and oil-water partition coefficient (10-fold enhanced). Diverse studies on the prepared complex using FTIR, DSC, PXRD and SEM studies ratified the formation of PLCs at 1:1 ratio. The PLCs were further incorporated onto NLCs, which were systematically optimized employing a face centered cubic design (FCCD), while evaluating for particle size, zeta potential, encapsulation efficiency and in vitro drug release as the CQAs. Caco-2 cell line studies indicated insignificant cytotoxicity, and P-gp efflux, while bi-directional permeability model and in situ perfusion studies specified enhanced intestinal permeation parameters. In vivo pharmacokinetic studies revealed notable increase in the values of C (4.7-fold) and AUC (2.1-fold), respectively, from PLCs-loaded NLCs vis-à-vis Mgf solution. In a nutshell, the promising results observed from the present research work signify enhanced biopharmaceutical attributes of the novel PLCs-loaded NLCs for potentially augmenting the therapeutic efficacy of Mgf.
芒果叶和茎皮中大量表达的芒果苷(Mgf)是一种有效的抗氧化剂。然而,由于其较差的水溶解度和不一致的胃肠道吸收、高肝首过代谢和高 P-糖蛋白外排,其体内活性大大降低。因此,本研究旨在通过制备负载 Mgf-磷脂复合物(PLCs)的纳米结构脂质载体(NLCs)来克服生物制药障碍。PLCs 和 NLCs 分别采用回流、溶剂蒸发和热乳化技术制备,Mgf 和 Phospholipon 90G 的摩尔比为 1:1;1:2;和 1:3。通过药物含量(96.57%)、水溶解度(提高了 25 倍)和油水分配系数(提高了 10 倍)等各种物理化学参数对复合物进行了评价。使用傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)、粉末 X 射线衍射(PXRD)和扫描电子显微镜(SEM)对制备的复合物进行了各种研究,证实了 1:1 比例下 PLCs 的形成。进一步将 PLCs 掺入到 NLCs 中,使用中心复合设计(CCD)对其进行系统优化,同时评估粒径、Zeta 电位、包封效率和体外药物释放作为关键质量属性(CQAs)。Caco-2 细胞系研究表明无明显细胞毒性和 P-糖蛋白外排,而双向渗透模型和原位灌注研究则指定了增强的肠渗透参数。体内药代动力学研究表明,与 Mgf 溶液相比,负载 PLCs 的 NLCs 显著增加了 C(4.7 倍)和 AUC(2.1 倍)的值。总之,本研究工作中观察到的有希望的结果表明,新型负载 PLCs 的 NLCs 具有增强的生物制药特性,有可能提高 Mgf 的治疗效果。